HYPE TO HIGH IMPACT: AI IMPLEMENTATION ACROSS
THE PHARMA VALUE CHAIN, FROM DISCOVERY TO DELIVERY

23 - 25 September, 2025 | Amsterdam

View Agenda

SPONSORSHIP OPPORTUNITIES

Book your place

Shameer Khader

Executive Director - Precision Medicine and Computational Biology Sanofi

Dr. Shameer Khader, currently Global Head of Computational Biology Cluster at Sanofi, brings over 15 years of leadership experience in building cross-functional teams and optimizing data and AI solutions in pharma, healthcare, and life sciences. He leads multiple, global teams with a focus on data science, AI, human genetics, and translational bioinformatics. His expertise spans clinical, pre-clinical, and post-clinical use cases. At Sanofi, Shameer’s team is developing an industry-leading, comprehensive disease research data ecosystem; integrating various data types to accelerate target identification, drug discovery and drug repositioning using advanced analytics approaches like knowledge graphs and large language models in the setting of precision medicine. Previously, he held key roles at AstraZeneca and renowned health systems like Mayo Clinic and Mount Sinai. Shameer holds a PhD in computational biology from NCBS – TIFR, Bangalore and an MPH from Imperial College, London, and completed post-doctoral training from Mayo Clinic. He has made substantial contributions to biomedicine with over 150 peer-reviewed papers, conference abstracts, and patents. His recent TEDx talk on Saving Lives using Data Science is available here: https://www.youtube.com/watch?v=ZM4u4XIhm08

Agenda Day 1

2:00 PM DRUG DESIGN - CASE STUDY: AI-driven drug discovery in the era of Generative AI and Large Language Models

In the ever-evolving landscape of drug discovery, clinical development, and drug repositioning; AI-driven approaches are revolutionizing the field, particularly with the advent of Generative AI and Large Language Models. These technologies offer unparalleled capabilities in analyzing massive-scale datasets, predicting molecular structure and function, and identifying potential drug candidates.

By comparing them with classical methods, such as high-throughput screening and molecular modeling, we can appreciate their efficiency and potential to accelerate the drug development process. However, along with the promising opportunities they bring, challenges such as data quality, interpretability, and ethical considerations must be carefully addressed. Ultimately, harnessing the power of AI in drug discovery holds immense promise for advancing therapeutic discovery and improving patient outcomes.

Check out the incredible speaker line-up to see who will be joining Shameer.

Download The Latest Agenda

In Partnership With :

QUESTIONS?